STOCK TITAN

CollPlant (NASDAQ: CLGN) VP Legal details options and RSU awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd VP Legal Abelis Bar Berta filed an initial ownership report showing equity awards tied to company performance and continued service. The filing lists options to purchase 20,000 ordinary shares at an exercise price of $7.50 expiring on March 28, 2033, with 13,750 options already vested and 6,250 vesting in five equal quarterly installments from March 28, 2026 through March 28, 2027. It also reports 13,000 restricted share units, of which 5,686 are vested and 7,314 vest in nine equal quarterly installments between June 8, 2026 and June 8, 2028, plus a separate grant of 40,000 restricted share units vesting over three years, with 33% vesting on November 25, 2026 and the remaining 67% in eight equal quarterly installments thereafter.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Abelis Bar Berta

(Last)(First)(Middle)
C/O COLLPLANT BIOTECHNOLOGIES LTD.
4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)
REHOVOT7670104

(City)(State)(Zip)

ISRAEL

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
VP Legal
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units(1)13,000(2)D
Restricted Share Units(1)40,000(3)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options to Purchase Ordinary Shares(1)(4)03/28/202403/28/2033Ordinary Shares20,000(4)$7.5D
Explanation of Responses:
1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
2. Of the restricted share units reported herein, 5,686 units are vested, and the remaining 7,314 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
3. The restricted share units shall vest over a period of 3 years as follows: 33% shall vest on November 25, 2026, and the remaining 67% shall vest in eight equal quarterly installments thereafter.
4. 13,750 options are fully vested and exercisable. The remaining 6,250 options shall vest and become exercisable in five equal quarterly installments beginning March 28, 2026 and ending March 28, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
/s/ Bar Abelis03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the CollPlant (CLGN) Form 3 filing by Abelis Bar Berta show?

The Form 3 shows VP Legal Abelis Bar Berta’s initial equity holdings, including stock options and restricted share units. It details award sizes, exercise price, expiration, and multi-year vesting schedules tied to continued service with CollPlant Biotechnologies Ltd.

How many stock options does the CollPlant (CLGN) VP Legal hold according to the Form 3?

The VP Legal holds options linked to 20,000 CollPlant ordinary shares at a $7.50 exercise price, expiring on March 28, 2033. Of these, 13,750 options are already vested, with 6,250 vesting in five equal quarterly installments from 2026 to 2027.

What restricted share unit (RSU) awards are reported for CollPlant (CLGN) VP Legal?

The filing reports 13,000 restricted share units and a separate 40,000-unit RSU grant. Part of the 13,000 units is already vested, while the remainder and the 40,000 units vest over structured quarterly schedules from June 2026 through a three-year period.

How do the CollPlant (CLGN) RSUs for Abelis Bar Berta vest over time?

Of the 13,000 RSUs, 5,686 are vested and 7,314 vest in nine equal quarterly installments from June 8, 2026 to June 8, 2028. The 40,000 RSUs vest 33% on November 25, 2026 and 67% in eight quarterly installments thereafter.

Is the CollPlant (CLGN) Form 3 a record of new insider buying or selling?

No, the Form 3 is an initial ownership statement, listing existing holdings rather than new market trades. It discloses equity awards, including options and RSUs, and explains their vesting terms, rather than reporting recent purchases or sales in the open market.

What conditions affect vesting of CollPlant (CLGN) VP Legal’s equity awards?

Vesting of options and restricted share units is subject to the VP Legal’s continued service with CollPlant. The awards follow detailed quarterly vesting schedules from 2026 through 2028, with portions vesting on specific dates and in specified installment patterns.
Collplant Biotechnologies Ltd

NASDAQ:CLGN

View CLGN Stock Overview

CLGN Rankings

CLGN Latest News

CLGN Latest SEC Filings

CLGN Stock Data

7.87M
8.97M
Biotechnology
Healthcare
Link
Israel
Rehovot